Read the latest updates and news on clinical trials for melanoma in the UK below.
THE MELANOMA TRIALFINDER
In May 2022, we are launching the Melanoma TrialFinder. This will support the melanoma community of patients and medical and nursing skin cancer professionals to provide knowledge and understanding of UK melanoma clinical trials.
The last decade has revolutionised melanoma treatments, particularly in stage 3 and 4 melanoma and this is thanks to the ongoing research in this area. Research provides hope.
THE FUTURE OF CLINICAL RESEARCH
Our ongoing commitment to research and clinical trials at Melanoma Focus is further validated by a recent policy paper released by the UK Government Department of Health and Social care. The paper calls for the need to focus on Clinical Research in all areas of patient care.
The policy paper, called Saving and Improving Lives: The Future of UK Clinical Research Delivery, defines the vision for the future of clinical research in one of its opening statements:
Our hope for the future:
“The pandemic has showcased the clear link between research and better outcomes – for individuals and the NHS….
…Clinical research is the single most important way in which we improve our healthcare – by identifying the best means to prevent, diagnose and treat conditions….
…Research is also vital in determining what doesn’t work, so we can improve best practice and focus resources on providing healthcare that delivers the greatest benefit to patients. And research extends beyond clinical trials for new medicines to cover a range of activities – from a study into a new approach to radiation therapy, to work to explore how a particular disease could be prevented, or even an investigation to help mitigate the side effects of a new
Clinical research is all around us and helps to improve the quality of healthcare patients receive. Crucially, these benefits are felt by everyone, not just those participating in research.For example, data shows NHS trusts that are highly research active have better outcomes for patients across their services.
As we look to tackle today’s major healthcare challenges….we must double-down on our commitment to clinical research.
This is how we will identify the best treatments, the best technologies and the best techniques to improve the lives of our children and our grandchildren…”
If you have advanced melanoma and are considering, or have started immunotherapy in the last 12 months, please watch this video about the DANTE trial, which aims to understand how long you should be treated with immunotherapy. The Dante Trial can be accessed at 39 hospitals across the UK. The team at Sheffield Teaching Hospitals NHS Trust have made a video to help patients better understand what this trial involves.
Remember to talk to your oncologist if you are interested in taking part or have any further questions.
CIRCULATING TUMOUR DNA MONITORING AND EARLY TREATMENT FOR RELAPSE: VIEWS FROM PATIENTS WITH EARLY-STAGE MELANOMA
Melanoma Focus helped to distribute information to patients asking them if they wanted to take part in a study to help understand patient views on a new blood test available to patients with early-stage melanoma.
Circulating tumour DNA (ctDNA) monitoring is a new technology that detects cancer DNA fragments in blood circulation. Regular monitoring with ctDNA has the potential to detect and treat cancer relapse earlier, but there is little evidence on patient acceptability. This study examines the views of patients with early-stage melanoma on the acceptability of the test and early treatment.
We currently have a clinical trial on our Melanoma TrialFinder that is researching the use of ctDNA; DETECTION trial.